Cargando…
Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab
Macrophage activation syndrome (MAS) is a rare and potentially fatal condition characterized by excessive activation and uncontrolled proliferation of T lymphocytes and macrophages, leading to overwhelming systemic inflammation and cytokine release. MAS has been reported with viral infections, autoi...
Autores principales: | Baker, Rahaf, Liew, Jean W., Simonson, Paul D., Soma, Lori A., Starkebaum, Gordon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087649/ https://www.ncbi.nlm.nih.gov/pubmed/30535729 http://dx.doi.org/10.1007/s10067-018-4387-5 |
Ejemplares similares
-
Central nervous system vasculitis in a patient with axial spondyloarthritis treated with infliximab: A case report and literature review
por: Panagopoulos, Panagiotis, et al.
Publicado: (2022) -
Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab
por: Otsuka, Akiyo, et al.
Publicado: (2015) -
Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019) -
Antiphospholipid Syndrome Associated with Nonradiographic Axial Spondyloarthritis
por: De Carvalho, Jozélio Freire, et al.
Publicado: (2021) -
Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial
por: Ducourau, Emilie, et al.
Publicado: (2020)